EP3868778A2 - Cdc45l-peptide und impfstoffe damit - Google Patents

Cdc45l-peptide und impfstoffe damit Download PDF

Info

Publication number
EP3868778A2
EP3868778A2 EP21160385.7A EP21160385A EP3868778A2 EP 3868778 A2 EP3868778 A2 EP 3868778A2 EP 21160385 A EP21160385 A EP 21160385A EP 3868778 A2 EP3868778 A2 EP 3868778A2
Authority
EP
European Patent Office
Prior art keywords
peptide
cdc45l
peptides
present
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21160385.7A
Other languages
English (en)
French (fr)
Other versions
EP3868778A3 (de
Inventor
Yasuharu Nishimura
Yusuke Tomita
Yusuke Nakamura
Takuya Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of EP3868778A2 publication Critical patent/EP3868778A2/de
Publication of EP3868778A3 publication Critical patent/EP3868778A3/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung

Definitions

  • amino acid analog refers to compounds that have the same basic chemical structure (an alpha carbon bound to a hydrogen, a carboxy group, an amino group, and an R group) as a naturally occurring amino acid but have one or more modified R group(s) or modified backbones (e.g., homoserine, norleucine, methionine, sulfoxide, methionine methyl sulfonium).
  • modified R group(s) or modified backbones e.g., homoserine, norleucine, methionine, sulfoxide, methionine methyl sulfonium.
  • amino acid mimetic refers to chemical compounds that have different structures but similar functions to general amino acids.
  • cancer refers to the cancers or tumors that overexpress the CDC45L gene, examples of which include, but are not limited to, testicular tumor, pancreatic cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, esophageal cancer, prostate cancer, chronic myeloid leukemia (CML), soft tissue tumor, gastric cancer, hepatobiliary cancer, and colorectal cancer.
  • testicular tumor pancreatic cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, esophageal cancer, prostate cancer, chronic myeloid leukemia (CML), soft tissue tumor, gastric cancer, hepatobiliary cancer, and colorectal cancer.
  • CML chronic myeloid leukemia
  • a polynucleotide may be synthesized using the solid phase techniques, as described in Beaucage SL & Iyer RP, Tetrahedron 1992, 48: 2223-311 ; Matthes et al., EMBO J 1984, 3: 801-5 .
  • the present invention also provides isolated antigen-presenting cells (APCs) that present complexes formed with HLA antigens and the peptides of the present invention on its surface.
  • APCs isolated antigen-presenting cells
  • the APCs may be derived from patients who are subject to treatment and/or prevention, and may be administered as vaccines by themselves or in combination with other drugs including the peptides of the present invention, exosomes, or CTLs.
  • the present invention also provides a method or process for manufacturing a pharmaceutical composition or agent for treating or preventing cancer or tumor, wherein the method or process includes the steps of admixing an active ingredient with a pharmaceutically or physiologically acceptable carrier, wherein the active ingredient is selected from among:
  • the pharmaceutical agents or compositions of the present invention can also contain nucleic acids encoding the peptide(s) disclosed herein in an expressible form.
  • the phrase "in an expressible form” means that the polynucleotide, when introduced into a cell, will be expressed in vivo as a polypeptide that induces anti-tumor immunity.
  • the nucleic acid sequence of the polynucleotide of interest includes regulatory elements necessary for expression of the polynucleotide.
  • a control level determined from a biological sample that is known to be non-cancerous is referred to as a "normal control level”.
  • the control level is determined from a cancerous biological sample, it is referred to as a "cancerous control level”.
  • Difference between a sample expression level and a control level can be normalized to the expression level of control nucleic acids, e.g., housekeeping genes, whose expression levels are known not to differ depending on the cancerous or non-cancerous state of the cell.
  • Exemplary control genes include, but are not limited to, beta-actin, glyceraldehyde 3 phosphate dehydrogenase, and ribosomal protein PI.
  • a subject to be treated by the present method is preferably a mammal.
  • Exemplary mammals include, but are not limited to, e.g., human, non-human primate, mouse, rat, dog, cat, horse, and cow.
  • the peptides may also be used as reagents to evaluate the efficacy of a vaccine.
  • PBMCs obtained from a patient vaccinated with an immunogen may be analyzed using, for example, either of the methods described above.
  • the patient is HLA typed, and peptide epitope reagents that recognize the allele specific molecules present in the patient are selected for the analysis.
  • the immunogenicity of the vaccine may be indicated by the presence of epitope-specific CTLs in the PBMC sample.
  • the host is preferably BL21 which expresses T7 RNA polymerase
  • the vector may also contain a signal sequence for peptide secretion.
  • An exemplary signal sequence that directs the peptide to be secreted to the periplasm of the E. coli is the pelB signal sequence ( Lei et al., J Bacteriol 169: 4379 (1987 )).
  • Means for introducing of the vectors into the target host cells include, for example, the calcium chloride method, and the electroporation method.
  • CDC45L small interfering (si) RNAs human Cdc45 siRNA, sc-35044: a pool of three target-specific 20-25 nt siRNAs; Santa Cruz
  • Lipofectamine (TM) 2000 (Invitrogen) was used to transfect the siRNAs into cells, according to the manufacturer's instructions.
  • GFP siRNAs were used as an irrelevant control. The treated cells were washed once with PBS, and adherent cells were collected at 72 h after transfection and used as target cells for the 51 Cr-release assay.
  • CDC45L specific CTLs were generated from the PBMCs of lung cancer patients positive for HLA-A24 by stimulation with the CDC45L-A24-9-109-2 (SEQ ID NO: 2), CDC45L-A24-9-294-3 (SEQ ID NO: 3), CDC45L-A24-9-556-4 (SEQ ID NO: 4), CDC45L-A24-9-370-7 (SEQ ID NO: 7) or CDC45L-A24-10-556-12 (SEQ ID NO: 12) peptide.
  • These CTL lines produced a significantly large amount of IFN-gamma in response to CDC45L derived peptides in IFN-gamma ELISPOT assays ( Fig. 5A ).
  • CDC45L-A2-9-556-4 SEQ ID NO: 4 specific CTLs from the PBMCs of a healthy donor positive for HLA-A2 (A ⁇ 0201) was generated by stimulation with the CDC45L-A2-9-556-4 (SEQ ID NO: 4) peptide.
  • the CTL lines generated from the HLA-A2 positive healthy donor produced IFN-gamma specifically in response to re-stimulation with T2 cells pulsed with the peptide ( Fig. 7A ).
  • the CTL lines exhibited specific lysis against CDC45L-A24-9-109-2 (SEQ ID NO: 2) peptide-pulsed C1R-A2402, but not against CDC45L-A24-9-294-3 (SEQ ID NO: 3), CDC45L-A24-9-556-4 (SEQ ID NO: 4) or irrelevant HIV-A24 peptide-pulsed C1R-A2402 in both healthy donor-4 and -5 ( Fig. 8C ).
  • CDC45L antigen is suggested to be highly immunogenic and a promising target for peptide-based immunotherapy of lung cancer without causing autoimmune phenomena.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21160385.7A 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit Withdrawn EP3868778A3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
EP17163532.9A EP3208334B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
PCT/JP2010/003488 WO2010137295A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same
EP19175920.8A EP3556857B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP10780256.3A EP2435567B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und diese enthaltende impfstoffe

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
EP17163532.9A Division EP3208334B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP19175920.8A Division EP3556857B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP19175920.8A Division-Into EP3556857B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP10780256.3A Division EP2435567B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und diese enthaltende impfstoffe

Publications (2)

Publication Number Publication Date
EP3868778A2 true EP3868778A2 (de) 2021-08-25
EP3868778A3 EP3868778A3 (de) 2021-11-03

Family

ID=43222423

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10780256.3A Not-in-force EP2435567B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und diese enthaltende impfstoffe
EP17163532.9A Active EP3208334B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP19175920.8A Active EP3556857B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP21160385.7A Withdrawn EP3868778A3 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP10780256.3A Not-in-force EP2435567B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und diese enthaltende impfstoffe
EP17163532.9A Active EP3208334B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit
EP19175920.8A Active EP3556857B1 (de) 2009-05-26 2010-05-25 Cdc45l-peptide und impfstoffe damit

Country Status (16)

Country Link
US (1) US8586547B2 (de)
EP (4) EP2435567B1 (de)
JP (1) JP5903697B2 (de)
KR (1) KR101765452B1 (de)
CN (3) CN103694315B (de)
AU (1) AU2010253356B2 (de)
BR (1) BRPI1010666B1 (de)
CA (3) CA3011607C (de)
DK (3) DK3556857T3 (de)
ES (3) ES2631952T3 (de)
IL (1) IL216211A (de)
MX (1) MX2011012619A (de)
RU (1) RU2562160C2 (de)
SG (1) SG176058A1 (de)
TW (1) TWI507204B (de)
WO (1) WO2010137295A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6124149B2 (ja) 2011-10-28 2017-05-10 オンコセラピー・サイエンス株式会社 Ｔｏｐｋペプチドおよびそれを含むワクチン
EP3202783A1 (de) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Manipulierte antigen-präsentierende zellen und deren verwendung
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida
IL273402B2 (en) 2017-09-19 2025-01-01 Univ British Columbia Antibodies against human leukocyte antigens type A2 and methods of using them
AU2018338423B2 (en) 2017-09-20 2025-06-26 Sangamo Therapeutics France Novel anti-HLA-A2 antibodies and uses thereof

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317688A (ja) 1986-03-28 1988-01-25 Kimiyoshi Tsuji ヒト―ヒトハイブリドーマの製造法
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
WO1999003499A1 (fr) 1997-07-16 1999-01-28 Institut National De La Sante Et De La Recherche Medicale Vesicule cellulaire denommee ''exosome'', leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
JPH11510507A (ja) 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
JP2000509281A (ja) 1996-04-30 2000-07-25 デューク ユニバーシティ Ｒｎａを添加された抗原提示細胞を用いる癌および病原体感染の治療方法
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
WO2003027322A2 (en) 2001-09-25 2003-04-03 Japan As Represented By The President Of The University Of Tokyo Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
US20040209295A1 (en) 2002-08-21 2004-10-21 Nikolai Franz Gregor Schwabe Chimeric MHC protein and oligomer thereof
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2261247A3 (de) * 2002-09-12 2011-02-16 Oncotherapy Science, Inc. KDR-Peptide und Impfstoffe damit
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP2298933A1 (de) * 2005-07-27 2011-03-23 Oncotherapy Science, Inc. Verfahren zur Diagnose von Ösophaguskrebs
EP2295570A1 (de) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Verfahren zur Diagnose von kleinzelligem Lungenkrebs
CN101472943B (zh) 2006-06-16 2013-07-17 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
JPS6317688A (ja) 1986-03-28 1988-01-25 Kimiyoshi Tsuji ヒト―ヒトハイブリドーマの製造法
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
JPH11510507A (ja) 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
JP2000509281A (ja) 1996-04-30 2000-07-25 デューク ユニバーシティ Ｒｎａを添加された抗原提示細胞を用いる癌および病原体感染の治療方法
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1999003499A1 (fr) 1997-07-16 1999-01-28 Institut National De La Sante Et De La Recherche Medicale Vesicule cellulaire denommee ''exosome'', leur preparation et utilisation dans la stimulation d'une reponse immunitaire
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
WO2003027322A2 (en) 2001-09-25 2003-04-03 Japan As Represented By The President Of The University Of Tokyo Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
US20040209295A1 (en) 2002-08-21 2004-10-21 Nikolai Franz Gregor Schwabe Chimeric MHC protein and oligomer thereof
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸

Non-Patent Citations (118)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Basics and Experiment of Peptide Synthesis", 1985, MARUZEN CO.
"Development of Pharmaceuticals (second volume", vol. 14, 1991, HIROKAWA, article "peptide synthesis"
"GenBank", Database accession no. NM 003504
"Peptide Synthesis", 1975, MARUZEN CO.
"The Proteins", vol. 2, 1976, ACADEMIC PRESS
ALTMAN, J. D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10330
ALTMAN, J. D. ET AL., SCIENCE, vol. 274, no. 5284, 1996, pages 94 - 96
APARICIO T ET AL., NUCLEIC ACIDS RES, vol. 37, 2009, pages 2087 - 95
BARANY G.MERRIFIELD R.B.: "Peptides", vol. 2, 1980, ACADEMIC PRESS, article "Solid Phase Peptide Synthesis", pages: 100 - 118
BAUERSCHMIDT C ET AL., GENES CELLS, vol. 12, 2007, pages 745 - 58
BEAUCAGE SLIYER RP, TETRAHEDRON, vol. 48, 1992, pages 2223 - 311
BENMOHAMED LKRISHNAN RLONGMATE JAUGE CLOW LPRIMUS JDIAMOND DJ, HUM IMMUNOL, vol. 1, no. 8, 6 August 2000 (2000-08-06), pages 764 - 79
BERTONI ET AL., J. CLIN. INVEST., vol. 100, 1997, pages 503 - 513
BETTS MR ET AL., J IMMUNOL METHODS, vol. 281, 2003, pages 65 - 78
BIRDWALKER, TRENDS BIOTECHNOL, vol. 9, 1991, pages 132 - 7
BOURGAULT VI ET AL., CANCER RES, vol. 64, 2004, pages 8761 - 70
BRICHARD VG ET AL., VACCINE, vol. 25, 2007, pages B61 - 71
BROWNING M ET AL., IMMUNOL TODAY, vol. 17, 1996, pages 165 - 70
BUNN PA, JR. ET AL., CONCLUSION. ONCOLOGIST, vol. 1, 2008, pages 37 - 46
BUUS S ET AL., TISSUE ANTIGENS., vol. 62, 2003, pages 378 - 84
CANCER RES, vol. 56, 1996, pages 5672 - 7
CLARK-CURTISSCURTISS ET AL., METHODS IN ENZYMOLOGY, vol. 101, 1983, pages 347 - 62
CLIN MICROBIOL REV, vol. 7, 1994, pages 277 - 89
COULIE, STEM CELLS, vol. 13, 1995, pages 393 - 403
DALBADIE-MCFARLAND ET AL., PROC NATL ACAD SCI USA, vol. 79, 1982, pages 6409 - 13
DATE, Y. ET AL., TISSUE ANTIGENS, vol. 47, 1996, pages 93 - 101
DERES ET AL., NATURE, vol. 341, 1989, pages 544 - 6
DUNBAR, P. R. ET AL., CURR. BIOL., vol. 8, 1998, pages 413
FASEB J, vol. 6, 1992, pages 2422 - 7
FENG D ET AL., CANCER RES, vol. 63, 2003, pages 7356 - 7364
FUKUSHIMA S ET AL., J IMMUNOTHER, vol. 32, 2009, pages 219 - 31
GALFREMILSTEIN, METHODS ENZYMOL, vol. 73, 1981, pages 3 - 46
GILBERT ET AL., NATURE BIOTECHNOL, vol. 15, no. 12, 1997, pages 1280 - 1284
GOLDSPIEL ET AL., CLINICAL PHARMACY, vol. 12, 1993, pages 488 - 505
HALL PA ET AL., DEVELOPMENT, vol. 106, 1989, pages 619 - 33
HARAO M ET AL., INT J CANCER, vol. 123, 2008, pages 2616 - 25
HASEGAWA S ET AL., CANCER RES, vol. 62, 2002, pages 7012 - 7
HIPP ET AL., IN VIVO, vol. 14, 2000, pages 571 - 85
HIRSCHOWITZ EA ET AL., PROC AM THORAC SOC, vol. 6, 2009, pages 224 - 32
HOOGENBOOMWINTER, J. MOL. BIOL., vol. 227, 1991, pages 381
HUSTON ET AL., PROC NATL ACAD SCI USA, vol. 85, 1988, pages 5879 - 83
IMAI K ET AL., CLIN CANCER RES, vol. 14, 2008, pages 6487 - 95
IMMUNOGENETICS, vol. 41, 1995, pages 178
INOUE M ET AL., IMMUNOL LETT, vol. 126, 2009, pages 67 - 72
J EXP MED, vol. 184, 1996, pages 465 - 72
J IMMUNOL, vol. 161, 1998, pages 5607 - 13
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 185, 1995, pages 181 - 190
K. S. KAWAMURA ET AL., J IMMUNOL, vol. 168, 2002, pages 5709 - 5715
K. S. KAWAMURA ET AL., J. IMMUNOL., vol. 168, 2002, pages 5709 - 5715
KARAKI SKARIYONE AKATO NKANO KIWAKURA YTAKIGUCHI M: "HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies", IMMUNOGENETICS, vol. 37, 1993, pages 139 - 42
KAWAKAMI ET AL., J IMMUNOL., vol. 142, 1989, pages 3452 - 3461
KOMORI H ET AL., CLIN CANCER RES, vol. 12, 2006, pages 2689 - 97
KONDO A ET AL., J IMMUNOL, vol. 155, 1995, pages 4307 - 12
KRIEGER: "A Laboratory Manual", 1990, STOCKTON PRESS, article "Gene Transfer and Expression"
KUBO RT ET AL., J IMMUNOL, vol. 152, 1994, pages 2968 - 76
KUZUSHIMA K ET AL., BLOOD, vol. 98, no. 6, 2001, pages 1872 - 81
LAFUENTE EM ET AL., CURRENT PHARMACEUTICAL DESIGN, vol. 15, 2009, pages 3209 - 3220
LALVANI, A. ET AL., J. EXP. MED., vol. 186, 1997, pages 859
LARSEN MV ET AL., BMC BIOINFORMATICS, vol. 8, 31 October 2007 (2007-10-31), pages 424
LEI ET AL., J BACTERIOL, vol. 169, 1987, pages 4379
LI JN ET AL., BMC CANCER, vol. 395, 2008, pages 395 - 8
MAKITA M ET AL., CLIN CANCER RES, vol. 8, 2002, pages 2626 - 31
MARK ET AL., PROC NATL ACAD SCI USA, vol. 81, 1984, pages 5662 - 6
MATHIASSEN S ET AL., EUR J IMMUNOL, vol. 31, 2001, pages 1239 - 46
MATTHES ET AL., EMBO J, vol. 3, 1984, pages 801 - 5
MIZUSHIMA ET AL., NUCLEIC ACIDS RES, vol. 18, no. 17, 1990, pages 5322
MONJI M ET AL., CLIN CANCER RES, vol. 10, 2004, pages 6047 - 57
MORGAN ET AL., J IMMUNOL, vol. 171, 2003, pages 3288
MORGANANDERSON, ANN REV BIOCHEM, vol. 62, 1993, pages 191 - 217
MORRISON J, J BACTERIOLOGY, vol. 132, 1977, pages 349 - 51
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
MULLIGAN, SCIENCE, vol. 260, 1993, pages 926 - 32
MURALI-KRISHNA, K. ET AL., IMMUNITY, vol. 8, 1998, pages 177
NAKAMURA T ET AL., ONCOGENE, vol. 23, 2004, pages 2385 - 400
NAKATSURA T ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 281, 2001, pages 936 - 44
NAKATSURA T ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 306, 2003, pages 16 - 25
NATURE MEDICINE, vol. 6, 2002, pages 631 - 637
NIELSEN M ET AL., PLOS ONE, vol. 2, 2007, pages e796
NIELSEN M ET AL., PROTEIN SCI, vol. 12, 2003, pages 1007 - 17
OGG ET AL., SCIENCE, vol. 279, 1998, pages 2103 - 2106
P. M. DAFTARIAN ET AL., J TRANS MED, vol. 5, 2007, pages 26
PARKER KC ET AL., J IMMUNOL, vol. 152, no. 1, 1 January 1994 (1994-01-01), pages 163 - 75
PARKIN DM ET AL., CA CANCER J CLIN, vol. 55, 2005, pages 74 - 108
PENNA ET AL., J EXP. MED., vol. 174, 1991, pages 1565 - 1570
PLUCKTHUNSKERRA, METHODS ENZYMOL, vol. 178, 1989, pages 497 - 515
POLLOK S ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 362, 2007, pages 910 - 5
POLLOK S ET AL., FEBS J, vol. 274, 2007, pages 3669 - 3684
PROTEIN SCIENCE, vol. 9, 2000, pages 1838 - 1846
R. P. M. SUTMULLER ET AL., J IMMUNOL, vol. 165, 2000, pages 7308 - 7315
ROMERO P ET AL., CLIN LUNG CANCER, vol. 9, 2008, pages S28 - 36
ROSENBERG S A ET AL., NAT MED, vol. 10, 2004, pages 909 - 15
ROUSSEAUX ET AL., METHODS ENZYMOL, vol. 121, 1986, pages 663 - 63
RUBIO V ET AL., NAT MED, vol. 9, 2003, pages 1377 - 82
RUTTINGER D ET AL., SURG ONCOL CLIN N AM, vol. 16, 2007, pages 901 - 18
S. O. DIONNE ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 52, 2003, pages 199 - 206
S. O. DIONNE ET AL., CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 53, 2004, pages 307 - 314
S. OTA ET AL., CAN RES, vol. 62, pages 1471 - 1476
SAHA P ET AL., J BIOL CHEM, vol. 273, 1998, pages 18205 - 9
SHATA ET AL., MOL MED TODAY, vol. 6, 2000, pages 66 - 71
SHEDLOCK ET AL., J LEUKOC BIOL, vol. 68, 2000, pages 793 - 806
STEVANOVIC S ET AL., NAT REV CANCER, vol. 2, 2002, pages 514 - 20
STOVER ET AL., NATURE, vol. 351, 1991, pages 456 - 60
T. K. HOFFMANN ET AL., J IMMUNOL., vol. 168, no. 3, 1 February 2002 (2002-02-01), pages 1338 - 47
TANIWAKI M ET AL., INT J ONCOL, vol. 28, 2006, pages 1481 - 75
TARN ET AL., J EXP. MED., vol. 171, no. l, 1990, pages 299 - 306
THOMAS KRCAPECCHI MR, CELL, vol. 51, 1987, pages 503 - 12
THOMSON ET AL., J IMMUNOL, vol. 157, no. 2, 1996, pages 822 - 826
THOMSON ET AL., PROC. NATL. ACAD. SCI USA, vol. 92, no. 13, 1995, pages 5845 - 5849
TOLSTOSHEV, ANN REV PHARMACOL TOXICOL, vol. 33, 1993, pages 573 - 96
TRENDS IN BIOTECHNOLOGY, vol. 11, no. 5, 1993, pages 155 - 215
VERHOEF ET AL., EUR J DRUG METAB PHARMACOKIN, vol. 11, 1986, pages 291 - 302
VERHOEYEN ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1536
WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 8
WUWU, BIOTHERAPY, vol. 3, 1991, pages 87 - 95
YOKOMINE K ET AL., INT J CANCER, vol. 126, 2009, pages 2153 - 63
ZAREMBA ET AL., CANCER RES, vol. 57, 1997, pages 4570 - 4577
ZOLLERSMITH, NUCLEIC ACIDS RES, vol. 10, 1982, pages 6487 - 500

Also Published As

Publication number Publication date
US20120164163A1 (en) 2012-06-28
AU2010253356B2 (en) 2015-09-24
CA3011607C (en) 2022-09-13
EP3556857A3 (de) 2019-12-04
BRPI1010666A2 (pt) 2017-09-12
CN103694315A (zh) 2014-04-02
IL216211A0 (en) 2012-01-31
ES2875950T3 (es) 2021-11-11
EP2435567B1 (de) 2017-05-03
EP3208334B1 (de) 2019-07-03
EP3868778A3 (de) 2021-11-03
ES2746334T3 (es) 2020-03-05
DK3556857T3 (da) 2021-07-12
CN102459589B (zh) 2013-12-25
CA2762934C (en) 2018-09-04
EP2435567A1 (de) 2012-04-04
CA3011607A1 (en) 2010-12-02
ES2631952T3 (es) 2017-09-06
EP2435567A4 (de) 2013-03-13
EP3556857B1 (de) 2021-05-05
CA2762934A1 (en) 2010-12-02
CA3167451A1 (en) 2010-12-02
AU2010253356A1 (en) 2011-12-01
RU2562160C2 (ru) 2015-09-10
EP3208334A2 (de) 2017-08-23
BRPI1010666B1 (pt) 2021-11-23
TW201106962A (en) 2011-03-01
EP3556857A2 (de) 2019-10-23
JP5903697B2 (ja) 2016-04-20
CN105153279A (zh) 2015-12-16
JP2012527867A (ja) 2012-11-12
KR20120018203A (ko) 2012-02-29
RU2011152975A (ru) 2013-07-10
MX2011012619A (es) 2012-01-30
IL216211A (en) 2016-06-30
KR101765452B1 (ko) 2017-08-07
DK2435567T3 (en) 2017-07-24
DK3208334T3 (da) 2019-09-30
CN102459589A (zh) 2012-05-16
WO2010137295A1 (en) 2010-12-02
CN105153279B (zh) 2018-09-11
SG176058A1 (en) 2011-12-29
EP3208334A3 (de) 2017-10-18
TWI507204B (zh) 2015-11-11
US8586547B2 (en) 2013-11-19
CN103694315B (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
US9045557B2 (en) NEIL3 peptides and vaccines including the same
EP3208334B1 (de) Cdc45l-peptide und impfstoffe damit
US8530430B2 (en) TTK peptides and vaccines including the same
HK40057055A (en) Cdc45l peptides and vaccines including the same
HK1242735A (en) Cdc45l peptides and vaccines including the same
HK1242735A1 (en) Cdc45l peptides and vaccines including the same
HK1242735B (en) Cdc45l peptides and vaccines including the same
HK40015530A (en) Cdc45l peptides and vaccines including the same
HK40015530B (en) Cdc45l peptides and vaccines including the same
HK1166098B (en) Cdc45l peptides and vaccines including the same
HK1166098A (en) Cdc45l peptides and vaccines including the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3556857

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3208334

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2435567

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20210930BHEP

Ipc: A61K 39/00 20060101ALI20210930BHEP

Ipc: C07K 14/47 20060101AFI20210930BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057055

Country of ref document: HK

17P Request for examination filed

Effective date: 20220307

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220905

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230117